Table 1.
Baseline characteristics of study participants
| Rifaximin group (n=72) | Placebo group (n=72) | |
|---|---|---|
| Female (n (%)) | 32 (44) | 29 (40) |
| Age (mo) | 47.6±6.5a | 46.8±7.6 |
| Mother alive (n (%)) | 72 (100) | 71 (99) |
| Father alive (n (%)) | 69 (96) | 69 (96) |
| Water source | ||
| Well (n (%)) | 61 (85) | 70 (97) |
| Borehole (n (%)) | 7 (10) | 1 (1) |
| Public tap (n (%)) | 1 (1) | 0 (0) |
| Weight-for-height Z-score | 0.13±0.72 | 0.16±0.82 |
| Weight-for-age Z-score | –0.96±0.93 | –0.86±0.95 |
| Height-for-age Z-score | –1.72±1.40 | –1.63±1.43 |
| Diarrhea in the week before study (n (%)) | 3 (4) | 1 (1) |
| Visible blood in stool in the week before study (n (%)) | 0 (0) | 0 (0) |
| Vomiting in the week before study (n (%)) | 2 (3) | 5 (7) |
| Abdominal pain in the week before study (n (%)) | 10 (14) | 11 (15) |
| Cough in the week before study (n (%)) | 11 (15) | 13 (18) |
| Rash in the week before study (n (%)) | 3 (4) | 1 (1) |
a
Mean±s.d. (all such values).